0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Increased Plasma Rifabutin Levels with Concomitant Fluconazole Therapy in HIV-Infected Patients

Carol Braun Trapnell, MD; Prem K. Narang, PhD; Ronald Li, PhD; and James P. Lavelle, MD
[+] Article and Author Information

From the Georgetown University Medical Center, Washington, D.C.; Food and Drug Administration, Rockville, Maryland; and Pharmacia, Inc., Columbus, Ohio. Acknowledgments: The authors thank Catherine O'Leary, RN, Mr. David James, and Mr. David Colborn for technical support and Darrell Abernethy, MD, PhD, Jerry Collins, PhD, and Charles W. Flexner, MD, for manuscript review. Grant Support: In part by Pharmacia, Inc., Columbus, Ohio. Requests for Reprints: Carol Braun Trapnell, MD, Food and Drug Administration, Center for Drug Evaluation and Research, 5600 Fishers Lane, HFD-900, Room 13B-16, Rockville, MD 20857. Current Author Addresses: Dr. Trapnell: Food and Drug Administration, Center for Drug Evaluation and Research, 5600 Fishers Lane, HFD-900, Room 13B-16, Rockville, MD 20857.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;124(6):573-576. doi:10.7326/0003-4819-124-6-199603150-00006
Text Size: A A A

Objective: To determine the effect of fluconazole on rifabutin pharmacokinetics.

Design: An open-label, crossover, phase 1 trial.

Setting: Outpatient clinical research center at a university medical center in Washington, D.C.

Patients: 12 persons with human immunodeficiency virus (HIV) infection whose CD4 lymphocyte counts were between 200 and 500 cells/mm3 and who were receiving maintenance therapy with zidovudine.

Intervention: Fluconazole, 200 mg/d for 2 weeks; then a combination of fluconazole, 200 mg/d, and rifabutin, 300 mg/d, for 2 weeks; and then rifabutin, 300 mg/d, for the final 2 weeks of the study.

Measurements: Blood and urine samples were obtained at regular intervals for 24 hours at the end of each 2-week dosing period to ascertain concentrations of fluconazole and rifabutin and the 25-desacetyl metabolite of rifabutin, LM565.

Results: Fluconazole significantly increased the plasma concentrations of both rifabutin and LM565. Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 ± 2404 ng · h/mL compared with 3025 ± 1117 ng · h/mL; P ≤ 0.05) for rifabutin and 216% (959 ± 529 ng · h/mL compared with 244 ± 141 ng · h/mL; P ≤ 0.05) for LM565.

Conclusions: Fluconazole significantly increases the systemic exposure of both rifabutin and LM565. This pharmacokinetic interaction offers a mechanism that may explain the changes reported in both the efficacy and toxicity of rifabutin with concomitant fluconazole therapy.

Figures

Grahic Jump Location
Figure 1.
Steady-state concentration compared with time curves of the plasma concentrations (mean ±SD) of rifabutin and its 25-desacetyl metabolite, LM565, over one dosing interval.

The dashed line indicates rifabutin alone; the solid line indicates rifabutin plus fluconazole.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Area under the plasma concentration-time curve for rifabutin and its 25-desacetyl metabolite, LM565, when rifabutin is administered alone and in combination with fluconazole.

Bars and error bars represent mean ±SD. Data on individual participants are joined by a solid line.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)